NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026

PUBT · 1d ago
NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026
  • NewAmsterdam Pharma scheduled new analyses from its Phase 3 obicetrapib program for presentation at ESC Congress 2026 in Munich.
  • Results will be presented in the future, starting Aug. 28, 2026, with additional sessions on Aug. 30-31.
  • Data focus on how stable lipoprotein(a) measurements are over the short term during treatment in late-stage trials.
  • Another presentation will summarize pooled on-treatment lipid-lowering effects across Phase 3 studies, supporting the drug’s overall efficacy profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260800PRIMZONEFULLFEED9815892) on August 26, 2026, and is solely responsible for the information contained therein.